Literature DB >> 23033888

Anti-cancer activity of novel dibenzo[b,f]azepine tethered isoxazoline derivatives.

Maralinganadoddi Panchegowda Sadashiva1, Shivananju NanjundaSwamy2, Feng Li2, Kanjoormana Aryan Manu2, Murugan Sengottuvelan3, Doddakunche Shivaramu Prasanna1, Nirvanappa Chikkagundagal Anilkumar4, Gautam Sethi2, Kazuyuki Sugahara3, Kanchugarakoppal Subbegowda Rangappa1.   

Abstract

BACKGROUND: Dibenzoazepine (DB) derivatives are important and valuable compounds in medicinal chemistry. The synthesis and chemotherapeutic properties of naturally occurring DBs and different heterocyclic moiety tethered DBs are reported. Herein, we report the DB-fused hybrid structure that containing isoxazolines (DBIs) and their anti-cancer activity, which could throw light on the structural and functional features of new molecules. RESULTS AND
CONCLUSION: The synthesis and characterization of novel ring DB tethered isoxazoline derivatives (DBIs) were carried out. After the detailed structural characterization using 2D-NMR experiments, the compounds were identified as 5-substituted isoxazolines. The effect of newly synthesized DBIs against the invasion of murine osteosarcoma (LM8G7) cells was studied. Among the tested molecules, compound 4g (5-[-3-(4-chlorophenyl)-4,5-dihydroisoxazol-5-yl-methyl]-5 H-dibenzo[b,f]azepine), was found to inhibit the invasion of LM8G7 cells strongly, when compared to other structurally related compounds. Cumulatively, the compound 4g inhibited the invasion MDA-MB-231 cells completely at 10 μM. In addition to anti-invasion property the compound 4g also inhibited the migration of LM8G7 and human ovarian cancer cells (OVSAHO) dose-dependently. Compound 4g inhibited the proliferation of LM8G7, OVSAHO, human breast cancer cells (MCF-7) and human melphalan-resistant multiple myeloma (RPMI8226-LR5) cells that are comparable to cisplatin and suramin.

Entities:  

Year:  2012        PMID: 23033888      PMCID: PMC3554437          DOI: 10.1186/1472-6769-12-5

Source DB:  PubMed          Journal:  BMC Chem Biol        ISSN: 1472-6769


  22 in total

Review 1.  Tricyclic and related drugs for nocturnal enuresis in children.

Authors:  C M A Glazener; J H C Evans; R E Peto
Journal:  Cochrane Database Syst Rev       Date:  2003

2.  Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers.

Authors:  Ahmed Kamal; S Prabhakar; M Janaki Ramaiah; P Venkat Reddy; Ch Ratna Reddy; A Mallareddy; Nagula Shankaraiah; T Lakshmi Narayan Reddy; S N C V L Pushpavalli; Manika Pal-Bhadra
Journal:  Eur J Med Chem       Date:  2011-05-30       Impact factor: 6.514

3.  Synthesis, characterization, antimicrobial and single crystal X-ray crystallographic studies of some new sulfonyl, 4-chloro phenoxy benzene and dibenzoazepine substituted benzamides.

Authors:  B S Priya; S Nanjunda Swamy; M V Tejesvi; G Sarala; S L Gaonkar; S Naveen; J Shashidhara Prasad; K S Rangappa
Journal:  Eur J Med Chem       Date:  2006-07-05       Impact factor: 6.514

4.  Synthesis, anticancer activity and apoptosis inducing ability of bisindole linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates.

Authors:  Ahmed Kamal; Y V V Srikanth; M Janaki Ramaiah; M Naseer Ahmed Khan; M Kashi Reddy; Md Ashraf; A Lavanya; S N C V L Pushpavalli; Manika Pal-Bhadra
Journal:  Bioorg Med Chem Lett       Date:  2011-10-31       Impact factor: 2.823

Review 5.  Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs).

Authors:  Dyeison Antonow; David E Thurston
Journal:  Chem Rev       Date:  2010-12-17       Impact factor: 60.622

6.  Enhancement in antimicrobial activity of 2-(phenyl)-3-(2-butyl-4-chloro-1H-imidazolyl)-5-butylate isoxazolidine.

Authors:  M P Sadashiva; H Mallesha; K Karunakara Murthy; K S Rangappa
Journal:  Bioorg Med Chem Lett       Date:  2005-04-01       Impact factor: 2.823

7.  Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines.

Authors:  I J Fidler; G L Nicolson
Journal:  J Natl Cancer Inst       Date:  1976-11       Impact factor: 13.506

8.  Synthesis of Dihydroisoxazole Nucleoside and Nucleotide Analogs.

Authors:  Hung-Jang Gi; Yuejun Xiang; Raymond F. Schinazi; Kang Zhao
Journal:  J Org Chem       Date:  1997-01-10       Impact factor: 4.354

9.  Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells.

Authors:  Feng Li; Prasana Priscilla Fernandez; Peramaiyan Rajendran; Kam M Hui; Gautam Sethi
Journal:  Cancer Lett       Date:  2010-01-06       Impact factor: 8.679

10.  Design, synthesis, and evaluation of new chemosensitizers in multi-drug-resistant Plasmodium falciparum.

Authors:  Jian Guan; Dennis E Kyle; Lucia Gerena; Quan Zhang; Wilbur K Milhous; Ai J Lin
Journal:  J Med Chem       Date:  2002-06-20       Impact factor: 7.446

View more
  9 in total

Review 1.  Nitrogen-Containing Heterocyclic Compounds Obtained from Monoterpenes or Their Derivatives: Synthesis and Properties.

Authors:  Vladimir V Chernyshov; Irina I Popadyuk; Olga I Yarovaya; Nariman F Salakhutdinov
Journal:  Top Curr Chem (Cham)       Date:  2022-08-11

2.  Development of 1-(4-(Substituted)piperazin-1-yl)-2-((2-((4-methoxybenzyl)thio)pyrimidin-4-yl)oxy)ethanones That Target Poly (ADP-Ribose) Polymerase in Human Breast Cancer Cells.

Authors:  Suresha N Deveshegowda; Prashant K Metri; Rashmi Shivakumar; Ji-Rui Yang; Shobith Rangappa; Ananda Swamynayaka; Muthu K Shanmugam; Omantheswara Nagaraja; Mahendra Madegowda; Priya Babu Shubha; Arunachalam Chinnathambi; Sulaiman Ali Alharbi; Vijay Pandey; Kwang Seok Ahn; Peter E Lobie; Basappa Basappa
Journal:  Molecules       Date:  2022-04-29       Impact factor: 4.927

3.  3,5-Disubstituted Isoxazole Derivatives: Potential Inhibitors of Inflammation and Cancer.

Authors:  Kodagahalli Sathya Rakesh; Swamy Jagadish; Kyathegowdanadoddi Srinivas Balaji; Farhan Zameer; Toreshettahally Ramesh Swaroop; Chakrabhavi Dhanajaya Mohan; Shankar Jayarama; Kanchugarakoppal Subbegowda Rangappa
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

Review 4.  Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis.

Authors:  Kanchugarakoppal S Rangappa; Kazuyuki Sugahara
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

5.  Design, Synthesis, Characterization, and Crystal Structure Studies of Nrf2 Modulators for Inhibiting Cancer Cell Growth In Vitro and In Vivo.

Authors:  Prathima Chikkegowda; Baburajeev C Pookunoth; Venugopal R Bovilla; Prashanthkumar M Veeresh; Zonunsiami Leihang; Thippeswamy Thippeswamy; Mahesh A Padukudru; Basavanagowdappa Hathur; Rangappa S Kanchugarakoppal; SubbaRao V Madhunapantula
Journal:  ACS Omega       Date:  2021-04-09

6.  Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression.

Authors:  HuaPing Li; HuaLi Li; HongJie Qu; MingZhu Zhao; Bo Yuan; MingHua Cao; JinQuan Cui
Journal:  Cancer Cell Int       Date:  2015-05-13       Impact factor: 5.722

7.  Experimental and theoretical study on structure-tautomerism among edaravone, isoxazolone, and their heterocycles derivatives as antioxidants.

Authors:  Auriekson N Queiroz; Camila C Martins; Kelton L B Santos; Ederson S Carvalho; Alex O Owiti; Karen R M Oliveira; Anderson M Herculano; Albérico B F da Silva; Rosivaldo S Borges
Journal:  Saudi Pharm J       Date:  2020-06-12       Impact factor: 4.330

Review 8.  A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers.

Authors:  Kamal Ahmed; Holly V Shaw; Alexey Koval; Vladimir L Katanaev
Journal:  Cancers (Basel)       Date:  2016-07-14       Impact factor: 6.639

9.  Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway.

Authors:  Chakrabhavi Dhananjaya Mohan; V Srinivasa; Shobith Rangappa; Lewis Mervin; Surender Mohan; Shardul Paricharak; Sefer Baday; Feng Li; Muthu K Shanmugam; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Andreas Bender; Gautam Sethi; Kanchugarakoppal S Rangappa
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.